SCHEMBL6097222

SCHEMBL6097222

COCCOc1cc2nncc(Nc3ccc(Br)cc3F)c2cc1OC

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.79
FLT1 P17948 13/20 0.79
FGFR1 P11362 11/20 0.79
EGFR P00533 11/20 0.55
RET P07949 2/20 0.55
KIF5B P33176 2/20 0.55
FLT4 P35916 8/20 0.55
FGFR2 P21802 3/20 0.53
FGFR4 P22455 3/20 0.53
FGFR3 P22607 3/20 0.53
PDGFRB P09619 3/20 0.53
FBP1 P09467 1/20 0.49
TEK Q02763 2/20 0.47
BMPR1B O00238 1/20 0.47
PLK4 O00444 1/20 0.47
CIT O14578 1/20 0.47
GAK O14976 1/20 0.47
EPHB6 O15197 1/20 0.47
RIPK2 O43353 1/20 0.47
ROCK2 O75116 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6098105 0.88 FLT1 (1.00) KDRFLT1FGFR1EGFRFLT4
SCHEMBL6099096 0.84 KDR (0.79) KDRFLT1FGFR1EGFRRET
SCHEMBL7864780 0.82 KDR (0.83) KDRFLT1FGFR1EGFRRET
SCHEMBL1194359 0.81 KDR (0.81) KDRFLT1FGFR1EGFRRET
Hydrochloric Acid SCHEMBL7866007 0.81 KDR (0.82) KDRFLT1FGFR1EGFRRET
SCHEMBL6097880 0.80 KDR (1.00) KDRFLT1FGFR1EGFRRET
SCHEMBL1468254 0.79 KDR (0.78) KDRFLT1FGFR1EGFRRET
SCHEMBL6098452 0.79 KDR (0.77) KDRFLT1FGFR1EGFRRET
Hydrochloric Acid SCHEMBL1467540 0.78 KDR (0.77) KDRFLT1FGFR1EGFRRET
SCHEMBL4772499 0.75 KDR (0.54) KDRFLT1FGFR1EGFRFBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7087602-B2 Cinnoline derivatives and use as medicine ASTRAZENECA UK LIMITED (GB) 2006-08-08 US disclosed
EP-0888310-B1 CINNOLINE DERIVATIVES AND USE AS MEDICINE ASTRAZENECA AB (SE) 2005-09-07 EP disclosed
US-20030199513-A1 Cinnoline derivatives and use as medicine ZENECA LIMITED 2003-10-23 US disclosed
US-6514971-B1 For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans ZENECA LIMITED (GB) 2003-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199513-A1 Cinnoline derivatives and use as medicine VEGFA, CNR1, CCR7 KDR 13/4885FLT1 5/4885FGFR1 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.